Workflow
ZACKS
icon
Search documents
Bear of the Day: MarineMax (HZO)
ZACKS· 2025-09-24 12:01
The market gave a little bit back from all-time highs Monday. It could tempt a lot of investors to blindly buy the dip. You’ve got to be extra careful during times like this. You want to try to avoid stocks that are all hype and no earnings. One way to uncover these potential pitfalls is by leaning on the Zacks Rank. Stocks in the good graces of our Zacks Rank have the strongest earnings trends. The opposite is true for stocks that are Zacks Rank #5 (Strong Sell) stocks.One such stock investors may want to ...
Bull of the Day: nVent Electric (NVT)
ZACKS· 2025-09-24 12:01
Company Overview - nVent Electric (NVT) is an industrial technology company focused on connection and protection, manufacturing products such as electrical enclosures, thermal management systems, and fastening solutions for various sectors including data centers, smart buildings, and renewable energy [2][5]. Earnings Momentum - nVent Electric has experienced significant earnings momentum, with 4 analysts raising their estimates for both the current year and the next over the past 60 days, resulting in a Zacks Rank 1 (Strong Buy) [3]. - The Zacks Consensus Estimate for 2025 has increased from $3.08 to $3.28, while 2026 estimates have risen from $3.47 to $3.74 [3]. Growth Projections - Current year EPS growth is projected at 31.73%, with next year expected to grow by another 13.8% [4]. - Revenue growth is anticipated to be 9% this year and 11.35% next year [4]. Market Positioning - nVent Electric is well-positioned to benefit from demand related to data center build-outs, electric vehicle (EV) charging, grid modernization, and global infrastructure upgrades, making it a compelling investment opportunity [5].
Almonty Industries Inc. (ALM) Moves 12.3% Higher: Will This Strength Last?
ZACKS· 2025-09-24 11:35
Company Overview - Almonty Industries Inc. (ALM) shares increased by 12.3% to close at $5.95, with a notable trading volume compared to typical sessions, and a total gain of 23.5% over the past four weeks [1][2] Project Development - The company has initiated a large-scale drilling program at its Sangdong Molybdenum Project in South Korea, planning to drill 26 holes over 11,700 meters to confirm molybdenum reserves [2][3] - Almonty holds an exclusive agreement to supply 100% of future molybdenum output from the Sangdong project to SeAH M&S, a subsidiary of the SeAH Group, in response to a molybdenum shortage in South Korea [3] Financial Performance - The upcoming quarterly earnings report is expected to show earnings of $0.00 per share, reflecting a year-over-year change of +100%, with revenues projected at $17.33 million, a 248% increase from the previous year [4] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not continue without trends in earnings estimate revisions [5] Industry Context - Almonty Industries is part of the Zacks Mining - Miscellaneous industry, where Teck Resources Ltd (TECK) also operates, having closed at $38.62 with a 0.3% decrease in the last trading session and a 16.3% return over the past month [6]
Should You Invest in the First Trust Indxx Aerospace & Defense ETF (MISL)?
ZACKS· 2025-09-24 11:20
Launched on October 25, 2022, the First Trust Indxx Aerospace & Defense ETF (MISL) is a passively managed exchange traded fund designed to provide a broad exposure to the Industrials - Aerospace & Defense segment of the equity market.An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs, transparency, flexibility, and tax efficiency; they are also excellent vehicles for long term investors.Sector ETFs also provide investors access to a broad group of ...
BigBear.ai (BBAI) Moves 12.9% Higher: Will This Strength Last?
ZACKS· 2025-09-24 11:01
BigBear.ai Holdings, Inc. (BBAI) shares soared 12.9% in the last trading session to close at $7.99. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 33.6% gain over the past four weeks.BigBear.ai shares likely jumped on key catalysts, including the VeriScan biometric launch at Nashville Airport, a U.S. Navy contract win and renewed AI stock enthusiasm fueled by rate-cut optimism.This company is expected to post quarterly loss of $ ...
Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last?
ZACKS· 2025-09-24 08:51
Company Overview - Karyopharm Therapeutics (KPTI) shares increased by 27.9% to close at $7.48, following a notable trading volume that exceeded typical levels, contrasting with a 7.3% loss over the past four weeks [1][2] Product Performance - The stock price surge is linked to positive investor sentiment regarding the strong uptake of Karyopharm's marketed product, Xpovio (selinexor), which is approved for multiple myeloma and B-cell lymphoma indications [2] Financial Expectations - Karyopharm is projected to report a quarterly loss of $3.67 per share, reflecting a year-over-year change of +5.9%, with expected revenues of $40.2 million, up 3.7% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Karyopharm Therapeutics is part of the Zacks Medical - Drugs industry, where another company, Akebia Therapeutics (AKBA), saw a 1.4% increase in its stock price, closing at $2.83, but has returned -7.9% over the past month [4] - Akebia's consensus EPS estimate for its upcoming report has also remained unchanged at -$0.02, representing an 80% improvement from the previous year [5]
Alvotech (ALVO) Surges 8.6%: Is This an Indication of Further Gains?
ZACKS· 2025-09-24 08:46
Alvotech (ALVO) shares rallied 8.6% in the last trading session to close at $8.7. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.7% loss over the past four weeks.Alvotech extended its rally for a second day, fueled by optimism after the EMA’s CHMP backed its regulatory filings for biosimilar versions of Amgen’s Prolia/Xgeva and J&J’s Simponi.This company is expected to post quarterly earnings of $0.08 per ...
Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?
ZACKS· 2025-09-23 23:56
Core Viewpoint - Pfizer plans to acquire Metsera for $4.9 billion, with potential total value reaching $7.3 billion including milestone payments, aiming to strengthen its position in the obesity drug market projected to be worth $100 billion by 2030 [1][3]. Group 1: Acquisition Details - The acquisition price is set at $47.50 per share, with milestone payments potentially increasing the total to $70 per share [1]. - Metsera's stock surged by 60% to over $50 following the acquisition announcement, while Pfizer's stock remained stable around $24 [2]. - Pfizer will finance the acquisition through cash and debt, while maintaining its dividend and capital priorities [2]. Group 2: Market Context - The obesity drug market is currently dominated by Eli Lilly and Novo Nordisk, with Eli Lilly's Zepbound controlling over 50% of the market and achieving an average weight reduction of 20.2%, compared to Novo Nordisk's Wegovy at 13.5% [4]. - Pfizer previously discontinued its own obesity drug, danuglipron, due to safety concerns [4]. Group 3: Financial Implications - The acquisition could help Pfizer mitigate the impact of upcoming patent expirations for key drugs like Eliquis and Ibrance [5]. - Metsera has raised $316.2 million through its IPO but is not expected to generate significant revenue in the near future [6]. - Pfizer's total sales are projected to slightly increase to $63.81 billion in the current year, with a slight decline expected in FY26 [12]. Group 4: Drug Pipeline - Metsera's MET-097i weight loss drug is in phase two trials, targeting hormones for weight loss and type 2 diabetes treatment [7]. - Metsera's MET-233i drug has shown promising results with an average weight loss of 8.4% in the first five weeks of phase 1 trials [7]. Group 5: Earnings Projections - Pfizer's EPS for FY25 is projected to increase to $3.14, while FY26 EPS is expected to decline to $3.08 [12]. - Metsera's FY25 EPS estimates have improved to a projected loss of -$2.79 per share, but FY26 estimates have worsened to -$3.64 [16].
Compared to Estimates, Micron (MU) Q4 Earnings: A Look at Key Metrics
ZACKS· 2025-09-23 23:30
Core Insights - Micron reported a revenue of $11.32 billion for the quarter ended August 2025, marking a 46% increase year-over-year, with EPS at $3.03 compared to $1.18 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $11.26 billion by 0.47%, and the EPS also surpassed the consensus estimate of $2.86 by 5.94% [1] Revenue Breakdown - DRAM revenue was $8.98 billion, exceeding the average estimate of $8.8 billion, representing a year-over-year increase of 68.7% [4] - Other technology revenue (primarily NOR) was $79 million, above the average estimate of $74.88 million, reflecting a year-over-year growth of 33.9% [4] - NAND revenue was $2.25 billion, slightly below the average estimate of $2.35 billion, showing a year-over-year decline of 4.8% [4] Stock Performance - Micron's shares have returned 41.4% over the past month, significantly outperforming the Zacks S&P 500 composite's 3.6% change [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating potential for outperformance in the near term [3]
Intrusion Inc. (INTZ) Declines More Than Market: Some Information for Investors
ZACKS· 2025-09-23 23:16
Company Performance - Intrusion Inc. closed at $1.89, reflecting a -3.08% change from the previous day, underperforming the S&P 500's loss of 0.55% [1] - Over the past month, shares of Intrusion Inc. gained 8.33%, which is below the Computer and Technology sector's gain of 9.88% but above the S&P 500's gain of 3.64% [1] Upcoming Earnings - Analysts expect Intrusion Inc. to report earnings of -$0.1 per share, indicating a year-over-year growth of 71.43% [2] - The Zacks Consensus Estimate for revenue is projected at $1.91 million, representing a 27.33% increase from the previous year [2] Full Year Estimates - For the full year, analysts anticipate earnings of -$0.38 per share and revenue of $7.74 million, reflecting changes of +76.69% and +34.03% respectively from last year [3] Analyst Estimates - Recent modifications to analyst estimates for Intrusion Inc. indicate shifting business dynamics, with upward revisions suggesting positive sentiment towards the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Intrusion Inc. at 4 (Sell) [6] Industry Context - The Computer - Networking industry, part of the Computer and Technology sector, holds a Zacks Industry Rank of 50, placing it in the top 21% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]